These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33851435)

  • 1. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Skou AS; Juul-Dam KL; Ommen HB; Hasle H
    Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
    Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
    Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
    Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
    Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
    Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
    Tiong IS; Loo S
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
    Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
    J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
    Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
    Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia.
    Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Banaclocha HM; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
    Clin Transl Oncol; 2023 May; 25(5):1446-1454. PubMed ID: 36598635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurable residual disease testing in acute myeloid leukaemia.
    Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
    Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.